ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,558 | -55.2% | 38 | -48.6% | 0.00% | – |
| Q1 2023 | $7,934 | -12.2% | 74 | 0.0% | 0.00% | – |
| Q4 2022 | $9,038 | +13.0% | 74 | -1.3% | 0.00% | – |
| Q3 2022 | $8,000 | -11.1% | 75 | -19.4% | 0.00% | – |
| Q2 2022 | $9,000 | +800.0% | 93 | +1228.6% | 0.00% | – |
| Q1 2022 | $1,000 | -93.8% | 7 | -94.3% | 0.00% | -100.0% |
| Q4 2021 | $16,000 | +6.7% | 122 | +29.8% | 0.00% | 0.0% |
| Q3 2021 | $15,000 | – | 94 | – | 0.00% | – |
| Q1 2021 | $0 | – | 0 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |